7 Recommendations for further research
7.1 The Committee recommended that the company collect data on people using the MiniMed Paradigm Veo system and successor technologies with low‑glucose suspend function, which should be analysed and published to show the system's impact on improving control of disabling hypoglycaemia. Key outcomes that could be presented include frequency and duration of hypoglycaemic events, time spent in hypoglycaemia, and number and duration of low‑glucose suspend events.
7.2 The Committee recommended further research to quantify the impact of hypoglycaemia on quality of life for people with type 1 diabetes and their carers. Future research should include adults and children and should capture the impact of persistent anxiety associated with the fear of catastrophic events related to severe hypoglycaemic events.
7.3 The Committee recommended further data collection to assess the impact of episodes of hypoglycaemia on healthcare resource use. The Committee noted that sources of routinely collected data, such as hospital episode statistics, the national diabetes audit and ambulance service call‑out data, could be combined to meet this objective.
7.4 The Committee recommended further research to investigate the clinical effectiveness of the integrated sensor‑augmented insulin pump therapy systems in younger children and pregnant women. No data are currently available for these subgroups and their inclusion in future studies is encouraged.
7.5 The Committee recommended that health economic models are developed to capture the impact of interventions on short‑term outcomes such as hypoglycaemia. In addition, the feasibility of incorporating more recently developed risk prediction models for cardiovascular disease such as QRisk2 and observational data from registries such as the Swedish National Diabetes Register into health economic models for type 1 diabetes should be explored.